Overdoses with Aripiprazole: Signs, Symptoms and Outcome in 239 Exposures Reported to the Danish Poison Information Centre
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Overdoses with Aripiprazole : Signs, Symptoms and Outcome in 239 Exposures Reported to the Danish Poison Information Centre. / Christensen, Amalie P; Boegevig, Soeren; Christensen, Mikkel B; Petersen, Kasper M; Dalhoff, Kim P; Petersen, Tonny S.
I: Basic & Clinical Pharmacology & Toxicology, Bind 122, Nr. 2, 2018, s. 293-298.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Overdoses with Aripiprazole
T2 - Signs, Symptoms and Outcome in 239 Exposures Reported to the Danish Poison Information Centre
AU - Christensen, Amalie P
AU - Boegevig, Soeren
AU - Christensen, Mikkel B
AU - Petersen, Kasper M
AU - Dalhoff, Kim P
AU - Petersen, Tonny S
N1 - © 2017 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society).
PY - 2018
Y1 - 2018
N2 - The aim of this study was to characterize the clinical signs and symptoms of exposures to aripiprazole overdoses. We retrospectively identified all aripiprazole exposures reported to the Danish Poison Information Centre (DPIC) from June 2007 to May 2015. Information concerning demographics, ingested dose and symptoms was extracted from the DPIC database and medical records. Information on death and admission to hospital was obtained from Danish national registers. We analysed 239 cases, 86 concerning single-drug exposures to aripiprazole, and 153 cases where aripiprazole had been taken with at least one other substance (mixed-drug). The median ingested aripiprazole dose was 105 mg (IQR: 50-1680 mg) in the single-drug exposure group and 120 mg (IQR: 60-225 mg) in the mixed-drug exposure group. The most commonly reported symptom was light sedation, reported in 63% of the single-drug group and 50% of the mixed-drug exposure group. There were no malignant arrhythmias or ECG abnormalities after single-drug exposures. No deaths were recorded in relation to the intake. We found a long-term mortality rate of 13 deaths per 1000 person-years (95% CI: 7; 23 per 1000 person-years), which is significantly higher than in an age- and gender-matched background population. In conclusion, we found that aripiprazole overdoses had few and mild symptoms predominantly related to the sedative properties. We detected a benign cardiovascular safety profile and no new safety concerns. Our findings may support an increased threshold of 300 mg for hospital admission after a single-drug exposure with aripiprazole and symptoms not worse than light sedation.
AB - The aim of this study was to characterize the clinical signs and symptoms of exposures to aripiprazole overdoses. We retrospectively identified all aripiprazole exposures reported to the Danish Poison Information Centre (DPIC) from June 2007 to May 2015. Information concerning demographics, ingested dose and symptoms was extracted from the DPIC database and medical records. Information on death and admission to hospital was obtained from Danish national registers. We analysed 239 cases, 86 concerning single-drug exposures to aripiprazole, and 153 cases where aripiprazole had been taken with at least one other substance (mixed-drug). The median ingested aripiprazole dose was 105 mg (IQR: 50-1680 mg) in the single-drug exposure group and 120 mg (IQR: 60-225 mg) in the mixed-drug exposure group. The most commonly reported symptom was light sedation, reported in 63% of the single-drug group and 50% of the mixed-drug exposure group. There were no malignant arrhythmias or ECG abnormalities after single-drug exposures. No deaths were recorded in relation to the intake. We found a long-term mortality rate of 13 deaths per 1000 person-years (95% CI: 7; 23 per 1000 person-years), which is significantly higher than in an age- and gender-matched background population. In conclusion, we found that aripiprazole overdoses had few and mild symptoms predominantly related to the sedative properties. We detected a benign cardiovascular safety profile and no new safety concerns. Our findings may support an increased threshold of 300 mg for hospital admission after a single-drug exposure with aripiprazole and symptoms not worse than light sedation.
KW - Accidents, Home
KW - Adolescent
KW - Adult
KW - Aged
KW - Antipsychotic Agents/poisoning
KW - Aripiprazole/poisoning
KW - Child
KW - Child, Preschool
KW - Consciousness/drug effects
KW - Denmark/epidemiology
KW - Drug Overdose/diagnosis
KW - Female
KW - Humans
KW - Infant
KW - Infant, Newborn
KW - Male
KW - Middle Aged
KW - Poison Control Centers
KW - Retrospective Studies
KW - Risk Assessment
KW - Suicide, Attempted
KW - Time Factors
KW - Treatment Outcome
KW - Young Adult
U2 - 10.1111/bcpt.12902
DO - 10.1111/bcpt.12902
M3 - Journal article
C2 - 28881461
VL - 122
SP - 293
EP - 298
JO - Basic and Clinical Pharmacology and Toxicology
JF - Basic and Clinical Pharmacology and Toxicology
SN - 1742-7835
IS - 2
ER -
ID: 221265110